Bork E - Search Results

1

Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.

Bork E, Hansen M, Dombernowsky P, Hansen SW, Pedersen AG, Hansen HH. Bork E, et al. J Clin Oncol. 1986 Apr;4(4):524-7. doi: 10.1200/JCO.1986.4.4.524. J Clin Oncol. 1986. PMID: 3007684

2

Teniposide in the treatment of small cell lung cancer: a review.

Hansen HH, Dombernowsky P, Hansen M, Bork E. Hansen HH, et al. Among authors: bork e. Semin Oncol. 1992 Apr;19(2 Suppl 6):65-8. Semin Oncol. 1992. PMID: 1329227 Review.

3

Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study.

Bork E, Ersbøll J, Dombernowsky P, Bergman B, Hansen M, Hansen HH. Bork E, et al. J Clin Oncol. 1991 Sep;9(9):1627-31. doi: 10.1200/JCO.1991.9.9.1627. J Clin Oncol. 1991. PMID: 1651994 Clinical Trial.

4

Phase II study of teniposide in small cell carcinoma of the lung.

Pedersen AG, Bork E, Osterlind K, Dombernowsky P, Hansen HH. Pedersen AG, et al. Among authors: bork e. Cancer Treat Rep. 1984 Oct;68(10):1289-91. Cancer Treat Rep. 1984. PMID: 6098366

5

Elevated plasma concentrations of C-flanking gastrin-releasing peptide in small-cell lung cancer.

Holst JJ, Hansen M, Bork E, Schwartz TW. Holst JJ, et al. Among authors: bork e. J Clin Oncol. 1989 Dec;7(12):1831-8. doi: 10.1200/JCO.1989.7.12.1831. J Clin Oncol. 1989. PMID: 2555450

6

A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.

Bork E, Vest S, Hansen HH. Bork E, et al. Eur J Cancer Clin Oncol. 1989 Oct;25(10):1403-11. doi: 10.1016/0277-5379(89)90097-7. Eur J Cancer Clin Oncol. 1989. PMID: 2591433

7

Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.

Sørensen JB, Hansen HH, Dombernowsky P, Bork E, Malmberg R, Aabo K, Bødker B, Hansen M. Sørensen JB, et al. Among authors: bork e. J Clin Oncol. 1987 Aug;5(8):1169-77. doi: 10.1200/JCO.1987.5.8.1169. J Clin Oncol. 1987. PMID: 3040918 Clinical Trial.

8

A phase I evaluation of N10-propargyl-5,8-dideazafolic acid.

Vest S, Bork E, Hansen HH. Vest S, et al. Among authors: bork e. Eur J Cancer Clin Oncol. 1988 Feb;24(2):201-4. doi: 10.1016/0277-5379(88)90253-2. Eur J Cancer Clin Oncol. 1988. PMID: 3356207

9

A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU).

Vibe-Petersen J, Bork E, Møller H, Hansen HH. Vibe-Petersen J, et al. Among authors: bork e. Eur J Cancer Clin Oncol. 1987 Dec;23(12):1837-43. doi: 10.1016/0277-5379(87)90049-6. Eur J Cancer Clin Oncol. 1987. PMID: 3436347

10

Peptide hormones in patients with lung cancer.

Hansen M, Bork E. Hansen M, et al. Among authors: bork e. Recent Results Cancer Res. 1985;99:180-6. doi: 10.1007/978-3-642-82533-0_20. Recent Results Cancer Res. 1985. PMID: 2999917 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters